The effect of baseline intraocular pressure and anterior segment parameters on intraocular pressure after intravitreal bevacizumab injection

References

• Presta LG, Chen H, O’Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57(20):4593–4599.
   PubMed Web of Science ®Google Scholar
• Parodi MB, Iacono P, Papayannis A, et al. Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia. Arch Ophthalmol. 2010;128(4):437–442. doi: 10.1001/archophthalmol.2009.408.
   PubMedGoogle Scholar
• Tufail A, Patel PJ, Egan C, et al. Bevacizumab for neovascular age related macular degeneration (ABC trial): multicentre randomised double masked study. BMJ. 2010;340:c2459. doi: 10.1136/bmj.c2459.
   PubMed Web of Science ®Google Scholar
• Pielen A, Feltgen N, Isserstedt C, et al. Efficacy and safety of intravitreal therapy in macular edema due to branch and Central retinal vein occlusion: a systematic review. PLoS One. 2013;8(10):e78538. doi: 10.1371/journal.pone.0078538.
   PubMed Web of Science ®Google Scholar
• Ozkiriş A. Intravitreal bevacizumab (avastin) for primary treatment of diabetic macular oedema. Eye (Lond)). 2009;23(3):616–620. doi: 10.1038/eye.2008.40.
   PubMed Web of Science ®Google Scholar
• Dorta P, Kychenthal A. Treatment of type 1 retinopathy of prematurity with intravitreal bevacizumab (avastin). Retina. 2010;30(4 Suppl):S24–S31. doi: 10.1097/IAE.0b013e3181ca1457.
   PubMedGoogle Scholar
• Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond)). 2013;27(7):787–794. doi: 10.1038/eye.2013.107.
   PubMed Web of Science ®Google Scholar
• de Vries VA, Bassil FL, Ramdas WD. The effects of intravitreal injections on intraocular pressure and retinal nerve fiber layer: a systematic review and meta-analysis. Sci Rep. 2020;10(1):13248. doi: 10.1038/s41598-020-70269-7.
   PubMed Web of Science ®Google Scholar
• Jeong S, Sagong M, Chang W. Acute angle closure attack after an intravitreal bevacizumab injection for branch retinal vein occlusion: a case report. BMC Ophthalmol. 2017;17(1):25. doi: 10.1186/s12886-017-0417-3.
   PubMedGoogle Scholar
• Kim IK, Baek J. A case of refractory acute angle closure glaucoma after an ıntravitreal bevacizumab ınjection. Korean J Ophthalmol. 2020;34(6):493–494. doi: 10.3341/kjo.2020.0083.
   PubMedGoogle Scholar
• Alkin Z, Perente I, Altan C, et al. Changes in anterior segment morphology after intravitreal injection of bevacizumab and bevacizumab-triamcinolone acetate combination. Eur J Ophthalmol. 2013;23(4):504–509. doi: 10.5301/ejo.5000241.
   PubMed Web of Science ®Google Scholar
• Levin AM, Chaya CJ, Kahook MY, et al. Intraocular pressure elevation Following ıntravitreal Anti-VEGF ınjections: Short- and long-term considerations. J Glaucoma. 2021;30(12):1019–1026. doi: 10.1097/IJG.0000000000001894.
   PubMed Web of Science ®Google Scholar
• Güler M, Capkın M, Simşek A, et al. Short-term effects of intravitreal bevacizumab on cornea and anterior chamber. Curr Eye Res. 2014;39(10):989–993. doi: 10.3109/02713683.2014.888452.
   PubMed Web of Science ®Google Scholar
• Arslan GD, Guven D, Alkan AA, et al. Short term effects of intravitreal anti-vascular endothelial growth factor agents on cornea, anterior chamber, and intraocular pressure. Cutan Ocul Toxicol. 2019;38(4):344–348. doi: 10.1080/15569527.2019.1616749.
   PubMed Web of Science ®Google Scholar
• Wen JC, Cousins SW, Schuman SG, et al. Dynamic changes of the anterior chamber angle produced by intravitreal anti-vascular growth factor injections. Retina. 2016;36(10):1874–1881. doi: 10.1097/IAE.0000000000001018.
   PubMed Web of Science ®Google Scholar
• Gumus G, Berhuni M, Ozturkmen C. The short-term effects of intravitreal bevacizumab injection on intraocular pressure, cornea, iridocorneal angle, and anterior chamber. Ther Adv Ophthalmol. 2022;14:25158414221133772. doi: 10.1177/25158414221133772.
   Web of Science ®Google Scholar
• Hui JLE, Subramanian S, Hussein A, et al. Changes of ocular biometry and ıntraocular pressure in patients treated with ıntravitreal ınjection of antivascular endothelial growth factors. Mal J Med Health Sci. 2022;18(5):144–150.
   Google Scholar
• Kerimoglu H, Ozturk BT, Bozkurt B, et al. Does lens status affect the course of early intraocular pressure and anterior chamber changes after intravitreal injection? Acta Ophthalmol. 2011;89(2):138–142. doi: 10.1111/j.1755-3768.2009.01656.x.
   PubMed Web of Science ®Google Scholar
• Chong RS, Sakata LM, Narayanaswamy AK, et al. Relationship ­between intraocular pressure and angle configuration: an anterior segment OCT study. Invest Ophthalmol Vis Sci. 2013;54(3):1650–1655. doi: 10.1167/iovs.12-9986.
   PubMed Web of Science ®Google Scholar
• Porporato N, Chong R, Xu BY, et al. Angle closure extent, anterior segment dimensions and intraocular pressure. Br J Ophthalmol. 2023;107(7):927–934. doi: 10.1136/bjophthalmol-2021-320453.
   PubMed Web of Science ®Google Scholar
• Nongpiur ME, Khor CC, Jia H, et al. ABCC5, a gene that influences the anterior chamber depth, is associated with primary angle closure glaucoma. PLoS Genet. 2014;10(3):e1004089. doi: 10.1371/journal.pgen.1004089.
   PubMed Web of Science ®Google Scholar
• Issa SA, Pacheco J, Mahmood U, et al. A novel index for predicting intraocular pressure reduction following cataract surgery. Br J Ophthalmol. 2005;89(5):543–546. doi: 10.1136/bjo.2004.047662.
   PubMed Web of Science ®Google Scholar
• Yang HS, Lee J, Choi S. Ocular biometric parameters associated with intraocular pressure reduction after cataract surgery in normal eyes. Am J Ophthalmol. 2013;156(1):89–94. e1. doi: 10.1016/j.ajo.2013.02.003.
   PubMed Web of Science ®Google Scholar
• Dackowski EK, Moon J-Y, Wang J, et al. The relationship between corneal biomechanics and ıntraocular pressure dynamics in ­patients undergoing intravitreal injection. J Glaucoma. 2021;30(5):451–458. doi: 10.1097/IJG.0000000000001833.
   PubMed Web of Science ®Google Scholar
• Maruyama-Inoue M, Inoue T, Mohamed S, et al. Incidence of elevated intraocular pressure after intravitreal injection in japanese patients with age-related macular degeneration. Sci Rep. 2021;11(1):12246. doi: 10.1038/s41598-021-91832-w.
   PubMed Web of Science ®Google Scholar
• Good TJ, Kimura AE, Mandava N, et al. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol. 2011;95(8):1111–1114. doi: 10.1136/bjo.2010.180729.
   PubMed Web of Science ®Google Scholar